Short communication · 31 Mar 2025
Conference abstract
Biosimilar products and competition
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Preventing relapse from early stage cancer is a major unsolved problem in oncology. After diagnosis of early stage colon cancer, the tumor is removed and often adjuvant chemotherapy is used for 6 or so months near maximum tolerated levels to prevent relapse. This is used for many early stage colon cancer patients of whom there will be 143,000 in 2013 in US. This therapy is only partially effective since 52,000 patients will die of metastatic colon cancer in 2013. In November 1994, I was diagnosed with Stage IIIc colon cancer. I had been doing cancer research for a number of years. The only drug available then was 5-flourouracil (5-FU) but how long should I use it? If we assume first that cancer growth is orderly, i.e., all cancer cells in the tumor divide once and only once during a doubling time, and second that the chemotherapy drug used is 100% effective, i.e., it kills every cell that tries to divide, then therapy duration should be one doubling time. Colon cancer volume doubling time is 2-3 months. Based on my estimates of tumor orderliness and 5-FU effectiveness, I calculated chemotherapy should ideally be used longer than 2 years. Nobody could tolerate a toxic protocol for 2 years or more. Therefore, I used low dose infusional 5-FU therapy at a non-toxic level for 2.5 years. This simple reasoning suggests that in order to be effective for all or nearly all cases, adjuvant chemotherapy for early stage colon cancer must be essentially nontoxic and used for over 2 years.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 2019
Strategic trends, current and future competitive landscape in biologics and biosimilars
Conference abstract · 25 Sep 2017
Strategic trends, current and future competitive landscape in biologics and biosimilars (follow-on biologics) drug development in USA and emerging markets-a brief snapshot from 2012 through 2022
Short communication · 8 Aug 2022
Adalimumab Biosimilar Adalimumab-adbm and Reference Product Population Pharmacokinetics in Healthy Persons and Patients with Rheumatoid Arthritis to Determine Pharmacokinetic Similarities
Short communication · 1 Dec 2020
Packaging Challenge for Affordable Biosimilar Products
More from this journal
The newest in Journal of Bioequivalence & Bioavailability.
Article · 5 Oct 2026
Long COVID in pediatric and young adult patients: a review of evaluation for microvascular changes, endothelial dysfunction, and arterial stiffness
Article · 12 Jun 2026
Advances in Bioavailability Through Innovative Drug Delivery Systems and Formulation Technologies
Article · 12 Jun 2026
Bioequivalence Study Design and Methodological Approaches in Generic Drug Evaluation
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Bioequivalence & Bioavailability
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Andrew Fischer Bourgoin”
